Our Aspire deals have been pretty good compared wh

Our Aspire deals have been pretty good compared what I'm used to seeing with early stage biotechs. In fact, one of my other biotechs recently did a financing where they sold shares and included warrants in the deal. Talk about dilution! I criticized that deal and used Leo and Aspire as an example of a much better way to acquire funding.

Quote:

---

ooops my bad.....I'm with you on P if it works in Phase2. OM trial has a ways to go...Looks like about 20 patients dosed as of Biotech conference....But who knows what's going on in Leo's mind. He sure does have a lot of choices to make a deal on....I just hope he doesn't choose Aspire. - takingabath

---